Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LERITINE vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LERITINE (anileridine) is a synthetic opioid analgesic that acts as a mu-opioid receptor agonist, modulating pain perception and emotional response to pain.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Management of moderate to severe pain,Anesthesia adjunct,Preoperative sedation
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
Adults: 25-50 mg orally every 6 hours as needed for pain; not to exceed 200 mg/day.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
2-3 hours (terminal half-life in adults; may be prolonged in hepatic impairment or elderly, dosing adjustments recommended)
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Hepatic metabolism via N-dealkylation and glucuronidation; CYP450 enzymes (likely CYP3A4) involved.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Renal (70-90% as unchanged drug and metabolites); biliary/fecal (10-30%)
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
85-95% bound primarily to alpha-1-acid glycoprotein and albumin
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
3-5 L/kg (extensive tissue distribution; high affinity for CNS and adipose tissue)
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Oral: 40-60% (first-pass metabolism); Intramuscular: 70-80%
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
GFR 30-60 m L/min: reduce dose by 25%; GFR 15-29 m L/min: reduce dose by 50% and administer every 8-12 hours; GFR <15 m L/min: avoid use.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50% and administer every 8-12 hours; Child-Pugh Class C: avoid use.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Weight-based: 0.5-1 mg/kg/dose orally every 6 hours as needed; maximum 4 mg/kg/day.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Age >65 years: start at lower end of dosing range (12.5-25 mg orally every 6 hours), monitor for CNS and respiratory depression.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
Risk of respiratory depression, addiction, abuse, misuse, and neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Respiratory depression, CNS depression, hypotension, biliary tract spasm, seizure threshold reduction, serotonin syndrome risk with MAOIs, tolerance/dependence, withdrawal, impaired mental/physical abilities.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Hypersensitivity to anileridine, significant respiratory depression, acute/suspected ileus, concurrent MAOI use or within 14 days.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
No specific food interactions are known; however, maintain a balanced diet and avoid grapefruit juice as it may affect metabolism.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
Pregnancy category D. First trimester: Increased risk of congenital malformations, particularly neural tube defects and cardiac anomalies; avoid if possible. Second and third trimesters: Risk of fetal dependence and withdrawal syndrome, decreased fetal breathing movements, and neonatal respiratory depression at delivery; prolonged use may cause neonatal opioid withdrawal syndrome.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Excreted into breast milk; relative infant dose >10%, risk of neonatal sedation and respiratory depression. M/P ratio unknown; avoid breastfeeding while on leritine. Consider alternative agents.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
Increased clearance during pregnancy may require higher doses to maintain analgesic effect. Close titration recommended; avoid during labor due to risk of neonatal respiratory depression.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
LERITINE (anileridine) is a potent opioid agonist with rapid onset; monitor for respiratory depression, especially in opioid-naïve patients. Avoid concurrent use with MAOIs. Use with caution in patients with hepatic impairment due to hepatic metabolism.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Avoid alcohol and other CNS depressants while taking LERITINE.,Do not drive or operate heavy machinery until you know how LERITINE affects you.,Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Store in a secure place away from children and pets.,Do not share this medication with others; it can cause addiction and death.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LERITINE vs ACTIQ, answered by our medical review team.
LERITINE is a Opioid Analgesic that works by LERITINE (anileridine) is a synthetic opioid analgesic that acts as a mu-opioid receptor agonist, modulating pain perception and emotional response to pain.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LERITINE and ACTIQ depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LERITINE is: Adults: 25-50 mg orally every 6 hours as needed for pain; not to exceed 200 mg/day.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LERITINE and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LERITINE is classified as Category C. Pregnancy category D. First trimester: Increased risk of congenital malformations, particularly neural tube defects and cardiac anomalies; avoid if possible. Second and third trime. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.